Northern Trust Corp Lyra Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 183,284 shares of LYRA stock, worth $34,823. This represents 0.0% of its overall portfolio holdings.

Number of Shares

183,284

Previous 83,860 118.56%

Holding current value

$34,823

Previous $23,000 104.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.24 - $0.34 $23,861 - $33,804	99,424 Added 118.56%	183,284 $47,000
Q2 2024 Aug 14, 2024	BUY	$0.26 - $6.25 $6,074 - $146,031	23,365 Added 38.62%	83,860 $23,000
Q1 2024 May 14, 2024	SELL	$4.55 - $6.53 $4,795 - $6,882	-1,054 Reduced 1.71%	60,495 $376,000
Q4 2023 Feb 13, 2024	BUY	$2.82 - $5.24 $12,802 - $23,789	4,540 Added 7.96%	61,549 $322,000
Q3 2023 Nov 13, 2023	BUY	$2.95 - $4.8 $80,523 - $131,020	27,296 Added 91.87%	57,009 $222,000
Q2 2023 Aug 11, 2023	SELL	$1.98 - $4.33 $229 - $502	-116 Reduced 0.39%	29,713 $122,000
Q2 2022 Aug 12, 2022	BUY	$4.12 - $7.51 $122,895 - $224,015	29,829 New	29,829 $169,000
Q2 2021 Aug 13, 2021	SELL	$6.91 - $12.59 $445,356 - $811,438	-64,451 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$10.38 - $15.61 $36,786 - $55,321	-3,544 Reduced 5.21%	64,451 $746,000
Q4 2020 Feb 11, 2021	BUY	$9.28 - $13.88 $177,322 - $265,219	19,108 Added 39.09%	67,995 $775,000
Q3 2020 Nov 16, 2020	SELL	$10.61 - $13.96 $31,511 - $41,461	-2,970 Reduced 5.73%	48,887 $547,000
Q2 2020 Aug 14, 2020	BUY	$10.91 - $18.56 $565,759 - $962,465	51,857 New	51,857 $587,000

Others Institutions Holding LYRA

# of Institutions

Shares Held

32M

Call Options Held

21.1K

Put Options Held

400

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $6.05M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Lyra Therapeutics, Inc. Transaction History